Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | n/a | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | n/a | n/a |
Pr/Book | n/a |
Latest | F'cast | |
---|---|---|
Revenue | n/a | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue ( m) | Pre-tax ( m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | n/a | (16.93) | (37.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | n/a | (21.18) | (42.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | n/a | (28.73) | (52.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | n/a | (30.94) | (48.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | n/a | (25.92) | (29.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
FDA Grants Orphan Drug Designation | 03-Mar-2025 | 12:05 | RNS |
Notice of Annual General Meeting | 28-Feb-2025 | 12:00 | RNS |
Positive EMA Opinion on Orphan Drug Designation | 27-Feb-2025 | 07:30 | RNS |
Traded | Action | Notifier | Price | Amount | Value |
---|---|---|---|---|---|
17-Sep-25 | Buy | Yrjö E K Wichmann | 94.50p | 30,000 | £28,348.51 |
17-Sep-25 | Exercise of option | Juho Jalkanen | 94.50p | 30,000 | £28,348.51 |
Currency | UK Pounds |
Share Price | 178.00p |
Change Today | -4.50p |
% Change | -2.47 % |
52 Week High | 262.50 |
52 Week Low | 141.67 |
Volume | 14,496 |
Shares Issued | 117.59m |
Market Cap | £209.32m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
11:46 | 635 @ 175.10p |
11:45 | 41 @ 177.50p |
11:05 | 1,000 @ 175.00p |
09:30 | 12,226 @ 177.00p |
09:21 | 1 @ 175.00p |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research